In vivo antiviral activity of ribavirin/alpha-cyclodextrin complex: Evaluation on experimental measles virus encephalitis in mice

International Journal of Pharmaceutics

Volumn 357, Issue 1-2, 2008, Pages 148-153

  Jeulin, H ^a   Grancher, N ^a   Kedzierewicz, F ^a   Finance, C ^a   Le Faou, A E ^a   Venard, V ^a  

^a NANCY UNIVERSITÉ   (France)

Author keywords

Cyclodextrin; Encephalitis; Measles virus; Ribavirin; RT PCR; Survival rate

Indexed keywords

ALPHA CYCLODEXTRIN; RIBAVIRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; LD 50; MALE; MEASLES VIRUS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; VIRUS ENCEPHALITIS; VIRUS LOAD;

ALPHA-CYCLODEXTRINS; ANIMALS; ANTIVIRAL AGENTS; DNA, COMPLEMENTARY; DNA, VIRAL; ENCEPHALITIS, VIRAL; FEMALE; MALE; MEASLES; MEASLES VIRUS; MICE; MICE, INBRED CBA; REFERENCE STANDARDS; RIBAVIRIN; RNA; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 42749087785     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.043     Document Type: Article

References (32)

1. Bussereau F., Picard M., Blancou J., and Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol. 32 (1988) 33-49
2. Dubes A., Degobert G., Fessi H., and Parrot-Lopez H. Synthesis and characterisation of sulfated amphiphilic alpha-, beta- and gamma-cyclodextrins: application to the complexation of acyclovir. Carbohydr. Res. 338 (2003) 2185-2193
3. Forni A.L., Schluger N.W., and Roberts R.B. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin. Infect. Dis. 19 (1994) 454-462
4. Frank D.W., Gray J.E., and Weaver R.N. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 83 (1976) 367-382
5. Gangemi J.D., Nachtigal M., Barnhart D., Krech L., and Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J. Infect. Dis. 155 (1987) 510-517
6. Gilbert B.E., and Wyde P.R. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob. Agents Chemother. 32 (1988) 117-121
7. Gilbert B.E., Wyde P.R., Wilson S.Z., and Robins R.K. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Antimicrob. Agents Chemother. 35 (1991) 1448-1453
8. Grancher N., Kedzierewicz F., Venard V., Marsura A., Finance C., and Le Faou A. Physicochemical study of ribavirin complexes with alpha-, beta- and gamma-cyclodextrins. J. Incl. Phenom. Macroc. Chem. 51 (2005) 149-157
9. Grancher N., Venard V., Kedzierewicz F., Ammerlaan W., Finance C., Muller C.P., and Le Faou A. Improved antiviral activity in vitro of ribavirin against measles virus after complexation with cyclodextrins. Antiviral Res. 62 (2004) 135-137
10. Griffin D.E., Mullinix J., Narayan O., and Johnson R.T. Age dependence of viral expression: comparative pathogenesis of two rodent-adapted strains of measles virus in mice. Infect. Immun. 9 (1974) 690-695
11. Honda Y., Hosoya M., Ishii T., Shigeta S., and Suzuki H. Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters. Antimicrob. Agents Chemother. 38 (1994) 653-655
12. Hosoya M., Mori S., Tomoda A., Mori K., Sawaishi Y., Kimura H., Shigeta S., and Suzuki H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob. Agents Chemother. 48 (2004) 4631-4635
13. Hovgaard L., and Brondsted H. Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins. Pharm. Res. 12 (1995) 1328-1332
14. Huffman J.H., Sidwell R.W., Khare G.P., Witkowski J.T., Allen L.B., and Robins R.K. In vitro effect of 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob. Agents Chemother. 3 (1973) 235-241
15. Ishii T., Hosoya M., Mori S., Shigeta S., and Suzuki H. Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis. Antimicrob. Agents Chemother. 40 (1996) 241-243
16. Jeulin H., Grancher N., Kedzierewicz F., Le Faou A.E., and Venard V. Evaluation by Q-RTPCR of the efficacy of ribavirin complexed with beta-cyclodextrin against measles virus in a mouse encephalitis model. Pathol. Biol. 54 (2006) 541-544
17. Kende M., Alving C.R., Rill W.L., Swartz Jr. G.M., and Canonico P.G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 27 (1985) 903-907
18. Kernahan J., McQuillin J., and Craft A.W. Measles in children who have malignant disease. Br. Med. J. (Clin. Res. Ed.) 295 (1987) 15-18
19. Lohmann C., Huwel S., and Galla H.J. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target 10 (2002) 263-276
20. Monnaert V., Tilloy S., Bricout H., Fenart L., Cecchelli R., and Monflier E. Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J. Pharmacol. Exp. Ther. 310 (2004) 745-751
21. Morrey J.D., Smee D.F., Sidwell R.W., and Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 55 (2002) 107-116
22. Muller C.P., Kremer J.R., Best J.M., Dourado I., Triki H., and Reef S. Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25 (2007) 1-9
23. Neighbour P.A., Rager-Zisman B., and Bloom B.R. Susceptibility of mice to acute and persistent measles infection. Infect. Immun. 21 (1978) 764-770
24. Niewiesk S., Brinckmann U., Bankamp B., Sirak S., Liebert U.G., and ter Meulen V. Susceptibility to measles virus-induced encephalitis in mice correlates with impaired antigen presentation to cytotoxic T lymphocytes. J. Virol. 67 (1993) 75-81
25. Prokai L., Prokai-Tatrai K., and Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med. Res. Rev. 20 (2000) 367-416
26. Schneider-Schaulies S., and ter Meulen V. Measles virus and immunomodulation: molecular bases and perspectives. Expert. Rev. Mol. Med. 2002 (2002) 1-18
27. Sidwell R.W., Allen L.B., Khare G.P., Huffman J.H., Witkowski J.T., Simon L.N., and Robins R.K. Effect of 1-beta-d-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob. Agents Chemother. 3 (1973) 242-246
28. Uekama K., and Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 1-40
29. Uhlmann V., Martin C.M., Sheils O., Pilkington L., Silva I., Killalea A., Murch S.B., Walker-Smith J., Thomson M., Wakefield A.J., and O'Leary J.J. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. J. Clin. Pathol.: Mol. Pathol. 55 (2002) 84-90
30. Wyde P.R., Moore-Poveda D.K., De Clercq E., Neyts J., Matsuda A., Minakawa N., Guzman E., and Gilbert B.E. Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob. Agents Chemother. 44 (2000) 1146-1152
31. Wyshak G., and Detre K. Estimating the number of organisms in quantal assays. Appl. Microbiol. 23 (1972) 784-790
32. Zhang M.-Q., and Rees D.C. A review of recent applications of cyclodextrins for drug discovery. Expert Opin. Ther. Pat. 9 (1999) 1697-1717